Showing 11 posts by Charles M. Johnson.
SB 273 – New Limits on Opioid Prescriptions Change the Game for West Virginia Hospitals and Physicians
On March 27, 2018, Governor James C. Justice signed SB 273, which among other dramatic actions limits initial opioid prescriptions in emergency rooms and also subsequent prescriptions by physicians in West Virginia, effective as of June 7, 2018. Read More ›
The response at the federal and local level is rapidly evolving to meet the overwhelming need to stem the opioid crisis. The numbers of deaths due to opioids in the United States increased from 28,647 in 2014 to 33,091 in 2015 and 42,249 in 2016 (an increase of 47% in two years). Read More ›
The West Virginia Medical Cannabis Advisory Board (“Advisory Board”) met on February 6, 2018, to review and consider comments made to proposed rules governing growers, processors, dispensaries, participating physicians and patients wishing to participate in the medical cannabis program. Read More ›
To Kentucky, the grass must have literally been greener on the other side. After Kentucky lawmakers watched their neighbors in Ohio and West Virginia enact medical marijuana laws, they introduced a 65-page bill at the Kentucky statehouse Thursday morning to legalize medical marijuana. Read More ›
In November of 2017, United States Attorney General Jeff Sessions announced that the Department of Justice (DOJ) would abide by the Rohrabacher–Blumenauer Amendment which has been interpreted as prohibiting the use of federal dollars to prosecute marijuana-industry participants in specific states that have legalized medical marijuana. Read More ›
On December 14, 2017, the West Virginia Medical Cannabis Advisory Board announced: (1) the results of informal surveys to gauge patient need and physician interest in participation in the new medical cannabis program scheduled to be rolled out July 1, 2019; and (2) proposed rules to govern the implementation of medical cannabis programs in West Virginia. Read More ›
Under the Obama administration, the Department of Justice (DOJ) placed a low priority on pursuing charges against individuals and entities complying with state-sanctioned medical marijuana programs. However, under President Trump and his appointee, Attorney General Jeff Sessions... Read More ›
On October 26, 2017, President Trump declared the Opioid Crisis a “public health emergency,” establishing a mechanism to devote considerable federal resources to help combat the growing opioid crisis, and setting in motion a coordinated approach by several federal agencies to focus on and eliminate this dire crisis. Read More ›
Substance Abuse Alert: West Virginia Expands Medicaid Program to Cover Naloxone Treatment, Methadone Treatment and Short-Term Residential Treatment for Substance Use Disorders
In 2015, West Virginia experienced the highest rate of deaths due to opioid overdoses in the United States, resulting in 41.5 deaths per 100,000 people, and a remarkable one-year increase in opioid deaths of 15%. The opioid crisis in West Virginia has garnered a lot of attention, including concerted efforts by the State and federal governments to increase the availability of treatment options to stem the crisis, especially for the Medicaid eligible population. Read More ›
West Virginia Physician Alert: Remember, You Are Recommending Medical Marijuana, Not Prescribing It.
In West Virginia, medical marijuana will soon be a treatment option for physicians and patients, and it’s vital that both parties understand the difference between a “prescription” and a “recommendation.” Otherwise, a physician may face serious sanctions if this is not made clear in all communications. Read More ›
Ask the Blogger
Do you have a topic that you would like discussed in a future blog article? Please let us know. If you have a confidential question regarding a blog article, please feel free to contact the article's author directly, or let us know if you would like for someone to contact you directly.
Brian F. Higgins is an associate in FBT's regulated business group with a focus on health care, and he has a history as corporate counsel to Medpace, Inc., a pharmaceutical clinical research organization.